ORION CORPORATION STOCK EXCHANGE RELEASE 12 APRIL 2017 at 12.00 noon EEST
Publishing of Orion Corporation’s Interim Report for January-March 2017 on 26 April 2017
Orion will publish Interim Report for January-March 2017 on Wednesday, 26 April 2017 approximately at 12:00 noon Finnish time (EEST). The release and related presentation material in Finnish and in English will be available on the Group’s homepage at www.orion.fi/en/investors promptly after the publishing.
News conference for analysts and media
A news conference for analysts and media will be held on Wednesday 26 April 2017 at 13:30 EEST at Hotel Kämp, address Pohjoisesplanadi 29, Helsinki. President and CEO Timo Lappalainen will give a brief presentation in English on the financial review. Questions can be asked after the result presentation also via teleconference.
Participants should be prepared to present a photo ID on request.
Live webcast and conference call
A link to the live webcast will be available at Orion’s website www.orion.fi/en/investors.
The conference call ID is 8575853 and the phone numbers to participate the conference are:
| Finland: | +358 (0)9 7479 0361 |
| Sweden: | +46 (0)8 5033 6574 |
| UK: | +44 (0)330 336 9105 |
| USA: | +1 719-325-2385 |
News conference recordings
A recording of the event in English and a recording of the presentation by the President and CEO in Finnish will be available on the Orion website later the same day.
Silent period
The silent period preceding the publication is ongoing and continues until the disclosure.
Orion Corporation
| Timo Lappalainen President and CEO | Jari Karlson CFO |
Contact person:
Terhi Ormio, Vice President Communications
tel. +358 10 426 4646
Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
Homepage: www.orion.fi
Orion is a globally operating Finnish pharmaceutical company - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion’s pharmaceutical R&D are central nervous system (CNS) disorders, oncology and respiratory for which Orion developes inhaled Easyhaler® pulmonary drugs. Orion’s net sales in 2016 amounted to EUR 1,074 million and the company had about 3,500 employees. Orion’s A and B shares are listed on Nasdaq Helsinki. Founded in 1917, Orion celebrates its centennial anniversary in 2017.
.
